Scientech Research LLC Makes New $675,000 Investment in GeneDx Holdings Corp. $WGS

Key Points

• Scientech Research LLC acquired 7,617 shares of GeneDx Holdings Corp. valued at approximately $675,000 in the 1st quarter, as reported in a recent SEC filing.
• Multiple institutional investors have increased their stakes in GeneDx, with Vanguard Group adding 25,116 shares and Summit Partners boosting its holdings by 336.9%.
• GeneDx reported a strong quarterly performance, with earnings per share (EPS) of $0.50, significantly surpassing analysts' estimates of $0.10, alongside a revenue of $102.69 million.

Scientech Research LLC purchased a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,617 shares of the company's stock, valued at approximately $675,000.

Several other large investors have also recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in shares of GeneDx during the 4th quarter valued at $35,000. GAMMA Investing LLC boosted its position in shares of GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after buying an additional 264 shares during the period. Comerica Bank purchased a new stake in shares of GeneDx during the fourth quarter worth $50,000. US Bancorp DE raised its holdings in shares of GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after acquiring an additional 548 shares in the last quarter. Finally, KBC Group NV bought a new position in GeneDx during the first quarter valued at about $81,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on WGS shares. Piper Sandler boosted their price target on GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday. Guggenheim restated a "buy" rating and issued a $115.00 price objective (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wells Fargo & Company increased their price objective on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $104.13.

Insider Activity at GeneDx

In other GeneDx news, Director Casdin Capital, Llc sold 500,000 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $120.90, for a total value of $60,450,000.00. Following the sale, the director owned 3,007,164 shares in the company, valued at approximately $363,566,127.60. This represents a 14.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason Ryan sold 38,072 shares of the stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the transaction, the director owned 103,284 shares in the company, valued at approximately $13,148,053.20. This trade represents a 26.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 561,641 shares of company stock worth $67,551,904 over the last ninety days. Corporate insiders own 29.60% of the company's stock.

GeneDx Stock Performance

GeneDx stock traded down $1.94 during mid-day trading on Friday, reaching $123.95. The company's stock had a trading volume of 311,806 shares, compared to its average volume of 1,018,995. GeneDx Holdings Corp. has a 12-month low of $35.88 and a 12-month high of $136.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The company has a market capitalization of $3.56 billion, a P/E ratio of 2,479.00 and a beta of 2.04. The firm's fifty day moving average price is $106.99 and its two-hundred day moving average price is $91.80.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The company had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. Sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.